|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | |  |  |  | | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | |  | | | | |  |  |  |  | | --- | --- | --- | --- | | |  |  |  | | --- | --- | --- | | |  | | --- | | [Community Pharmacy England logo](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=2692f02e44&e=d19e9fd41c) |  |  | | --- | | **Newsletter**  30th September 2024 | | | | | |  |  | | --- | --- | | |  | | --- | | The voice of community pharmacy (banner) | | | |  |  | | --- | --- | | |  | | --- | | **This newsletter - sent on Mondays, Wednesdays and Fridays - contains important information and resources to support community pharmacies across England.** | | | | |  | | --- | |  | | | |  |  | | --- | --- | | |  | | --- | | **In this update: Pharmacy First thresholds; Our 2023/24 Annual Report; Oxbryta tablets recall.** | | | | |  | | --- | |  | | | |  | | --- | |  | | | |  |  | | --- | --- | | |  | | --- | | Pharmacy owners have been increasingly worried about meeting the monthly Pharmacy First payment thresholds, especially with the October increase to 30 clinical pathways approaching.  Community Pharmacy England has been discussing this issue over the last few weeks with the Department of Health and Social Care and NHS England, and Ministers have now decided that they intend to **reduce the October threshold for the Pharmacy First service to 20**, in light of the concerns that we have raised. | | |  |  |  | | --- | --- | | |  | | --- | |  | | | |  |  | | --- | --- | | |  | | --- | | New consultation caps, based on actual pharmacy delivery levels, will also be introduced **from tomorrow, 1st October**. | | | | |  | | --- | | [**Read more, including the Drug Tariff determination and Janet's full statement**](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=b1d56ed23f&e=d19e9fd41c) | | | |  | | --- | |  | | | |  |  | | --- | --- | | |  | | --- | | **Our 2023/24 Annual Report** | | | | |  |  | | --- | --- | | |  | | --- | | We have today published our [annual report for 2023/24](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=b336acda75&e=d19e9fd41c), showcasing the extensive work done on behalf of community pharmacy owners over the past year.   Key highlights include negotiations on the new Pharmacy First service and support for pharmacy owners with national services; ongoing work to monitor margin and payments; financial and economic work to show the impossible funding squeeze; political influencing work ahead of the General Election; and a wide range of governance and regulatory work.   It was a critical year for the sector with the launch of Pharmacy First; but also an incredibly difficult one for all pharmacy owners given the ongoing intolerable financial and operational pressures, and the very worrying rate of pharmacy closures.  The report also details the progress we have made in advocating for sector investment and expanding services, as well as the support we have given pharmacy owners and LPCs, ranging from publishing toolkits to holding engagement events. | | |  |  |  | | --- | --- | | |  | | --- | | [**Read more and access the report**](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=935ab9e84e&e=d19e9fd41c) | | | |  |  | | --- | --- | | |  | | --- | | As well as producing a full report, we have developed some animations to capture, in a nutshell, some of our key efforts in this critical year. Please click the hyperlinks to watch.   * [Animation 1: The strategy for Community Pharmacy](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=2d9de03ff5&e=d19e9fd41c) * [Animation 2: Impact](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=e4e47b9a6f&e=d19e9fd41c) | | | | |  | | --- | |  | |  |  |  | | --- | --- | | |  | | --- | |  | | | |  |  | | --- | --- | | |  | | --- | | **Class 2 Medicines Recall: Oxbryta (voxelotor) 500mg Tablets (Pfizer Limited)**  All batches of Oxbryta (voxelotor) 500mg Tablets are being recalled after clinical trials revealed an increased risk of vaso-occlusive crises and fatal events in patients.  [L](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=874dae8791&e=d19e9fd41c)[**earn more, including important advice for healthcare professionals**](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=d61cfe1eea&e=d19e9fd41c) | | | | |  | | --- | |  | | | |  | | --- | | [Community Pharmacy England banner](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=5ba41eb8c1&e=d19e9fd41c) | | | |  | | --- | |  | | | | |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | |  |  |  | | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | | [Twitter](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=e37833880a&e=d19e9fd41c) | | | | |  |  |  | | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | | [Facebook](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=54bb62a51d&e=d19e9fd41c) | | | | |  |  |  | | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | | [LinkedIn](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=39cf2d228b&e=d19e9fd41c) | | | | |  |  |  | | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | | [Website](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=f10878bd6e&e=d19e9fd41c) | | | | | | | | | |  |  | | --- | --- | | |  | | --- | | **Community Pharmacy England** Address: 14 Hosier Lane, London EC1A 9LQ Tel: 0203 1220 810 | Email: [comms.team@cpe.org.uk](mailto:comms.team@cpe.org.uk)  *Copyright © 2024 Community Pharmacy England, All rights reserved.*  You are receiving this email because you are subscribed to our newsletters. Please note Community Pharmacy England is the operating name of the Pharmaceutical Services Negotiating Committee (PSNC). | | | | | |

